How to Choose a PR agency for Clinical research organizations

By Aidan Sowa, CEO and Founder, Frontier Industries | October 2026

A contract research organization sells something no brochure can photograph: other people's confidence that a difficult trial will finish. Sponsors hand you their compound, their timeline and their credibility with investors. Sites hand you their scarcest resource, coordinator hours. Patients hand you their bodies and their Saturdays. This guide applies one selection principle: your agency must be able to speak to all three lenders at once, in three different registers, without a single claim that any of them can disprove. Most agencies can manage one register. Your business runs on three.

I. Discrimen

You do not sell research services, you sell transferred risk

A sponsor choosing between CROs is not comparing capabilities decks. It is deciding whose name absorbs the blame when enrollment slips, when a site underperforms, when a protocol amendment lands mid study. Your reputation is therefore priced like insurance: sponsors pay premiums to firms whose public record suggests fewer surprises.

This distinction changes what PR is for. A consumer agency will offer you awareness. A CRO needs evidence of temperament: how your firm writes about delays, how it talks about patients, how its leaders behave in trade press when a trial fails through no one's fault. Evaluate agencies on whether they understand that your marketing is a risk document read by procurement lawyers.

Nobody buys a trial. They buy the right to stop worrying about one.

II. Machina

The recruitment economy decides whose story gets believed

The machine under this industry is enrollment arithmetic. Tufts Center for the Study of Drug Development research on 150 global trials found that 9 out of 10 studies eventually reached their enrollment goals, but many took up to twice the planned time to do it (Imperial CRS summary of Tufts CSDD). The same research put hard edges on site performance: 11 percent of sites enrolled not one patient, 37 percent under enrolled, 39 percent met target and 13 percent exceeded it (Tufts CSDD).

Your agency works inside those numbers whether it knows them or not. Sponsors have lived them, which is why sponsor facing claims about recruitment speed are audited against bitter experience. A communications partner that has never heard of Tufts, CISCRP or site activation benchmarks will write copy your buyers discount on sight. Ask in the first meeting. The answer predicts the relationship.

In this market, a timeline promise is a debt. Your agency should know the interest rate.

Site activation deserves the same respect as enrollment in your communications, because sponsors feel both. The RAPS summary of the Tufts site activation research describes how activation speed and enrollment performance vary sharply by region and by how realistically targets were set, with North American and Asian sites activating fastest in the benchmarked phases (RAPS). A CRO that publishes its own activation medians, broken out by phase and region, gives sponsors something they can put in front of their own governance boards. Almost none do, because the numbers are unflattering in places. That is precisely why publishing them works: it signals a firm that measures itself the way its customers measure it.

III. Exemplum

Two CROs, one protocol, opposite public habits

Picture two mid size firms bidding for the same oncology study. The first publishes its recruitment science: feasibility methods, site selection criteria, a candid post on why CNS trials overrun, citing Tufts analysis showing enrollment driven extensions averaging 116 percent of planned time in that area (RAPS summary of Tufts CSDD). The second firm publishes award announcements and a promise to enroll faster than anyone.

Sponsors have been burned by the second firm's genre for thirty years, so they weight the first firm's paper trail heavily. Meanwhile later Tufts benchmarking found genuine improvement across the industry, with enrollment timelines equal to or better than planned in 77 percent of studies in the updated analysis (Applied Clinical Trials, 2020), which means credible firms can now prove performance the older data said was rare. The example cuts one way: the firms that document reality win the argument against firms that decorate it.

Candour about slow trials is the fastest credibility a CRO can buy.

IV. Damnum

Retention failure is a reputational leak, not just an operational one

Enrollment gets the headlines, but dropout quietly reprices your firm. The updated Tufts benchmarks recorded late development dropout rates averaging 19.1 percent in 2019, up from 15.3 percent in 2012 (Applied Clinical Trials, 2020). Every participant who leaves mid study represents a protocol burden someone underestimated, a site relationship strained, and a data set weakened.

Now translate that into communications terms. Patient communities talk. Condition specific forums carry detailed accounts of confusing consent processes, travel burdens and sites that treated participants as inventory. Sponsors read those threads during vendor selection more often than your agency will ever know. A CRO whose public voice shows genuine fluency in participant experience, scheduling burden, compensation fairness and plain language results return will be graded differently from one whose patient materials read like legal disclaimers with a logo.

Participants are the only audience in this industry who can review you from inside the product.

Retention is also where your communications and your operations either agree or get caught disagreeing. A firm can publish beautiful participant centricity essays while its sites schedule visits at hours working people cannot attend and its compensation arrives months late. Participants compare notes publicly now, in condition communities with long memories, and sponsors increasingly read those communities during diligence. Your agency should be auditing the gap between your participant facing promises and your sites' actual practice, then closing it from the operations side first. Communications that describe a burden you have not actually reduced will be corrected by the people carrying it, in public, with screenshots.

V. Genus

The variable that moved is where the trial happens

Decentralization rewired what sponsors ask and what patients expect. The FDA issued final guidance on conducting trials with decentralized elements in September 2024, covering telehealth visits, in home activities, local healthcare providers and digital tools (NSF summary of FDA guidance, 2024). A Freyr analysis of the guidance stresses the operational fine print: which tasks local providers may perform, what must stay with trained trial staff, and who remains responsible for consent (Freyr Solutions, 2024).

Your agency needs operational literacy here, because the story opportunities and the risk sit in the same details. A firm that can explain, accurately, how remote data acquisition changes site economics and participant diversity is employable. A firm that treats decentralized trials as a buzzword will produce content sponsors' medical teams correct in red ink, in front of you.

Decentralized is a logistics claim before it is a marketing one. Staff accordingly.

The guidance landscape also hands you a content discipline worth copying. The FDA's framework, and the industry analyses built on it, return obsessively to one theme: responsibility cannot be delegated away. Sponsors remain accountable for work performed by local providers, vendors and technology platforms (Crucial Data Solutions regulatory timeline, 2026). CROs live under the mirror image of that rule: your name carries work performed by sites you do not employ. An agency that internalises this will build your communications around verification, what you check, how often, what you do with failures, rather than around the comforting fiction of control. Sponsors, who carry the regulatory version of the same burden, recognise the temperament instantly and price it into shortlists.

VI. Regio

Segment by who lends you what

An agency plan that merges these audiences into one stakeholder list will fail each of them politely. Demand separate strategies: sponsor facing thought leadership, site facing respect, participant facing clarity. The connective tissue is a single factual spine about how your firm actually runs studies, from activation timelines to amendment discipline. If the spine does not exist, no agency can invent it for you without creating the kind of claims this industry punishes.

Each audience grades a different exam. Bring five answers, not one slogan.

VII. Occasio

Participation is the open brief nobody has fully claimed

The regulatory wind favours firms that widen who trials reach. FDA's decentralized elements guidance was driven partly by access goals, and the agency followed with guidance on enhancing participation in clinical trials (IntuitionLabs regulatory review, 2026). Community based execution, mobile visits and local facility partnerships are becoming the practical route to representative enrollment (Clinical Trial Vanguard, 2025).

For a CRO, this is a communications opening the giants have not sealed. The large firms publish diversity commitments at corporate altitude. A mid size firm that documents actual practice, neighbourhood partnerships, translated materials, evening visit windows, transport support, can own the credible version of this story in its therapeutic niches. Your agency should be pressing you for that documentation, with numbers your compliance team clears, instead of asking for another executive headshot.

Commitments are wallpaper. Documented practice is news.

The talent market rides on the same opening. Coordinators, research nurses and data managers choose employers partly on public reputation, and a CRO visibly serious about participant experience and site respect attracts the staff whose performance sponsors are actually buying. Your agency should be treating recruitment communications as part of the same story, because in a capacity constrained industry the firm that hires the coordinators wins the feasibility meetings that follow.

VIII. Structura

Specialisation beats scale when the buyer is an expert

Sponsors are among the most expert buyers in this entire library of industries. They discount generality professionally. That is why a focused CRO with a genuine record in one therapeutic area, publishing rigorous content in that area's journals and conferences, routinely out positions diversified giants in the conversations that precede an RFP. Structure, evidence and specificity defeat budget.

Apply the same logic to agency choice. A modest agency whose partners have covered clinical operations for a decade will usually serve you better than a famous healthcare practice that assigns you its available generalists. Inspect the actual humans: who attends your scientific advisory meetings, who drafts, who has sat through a protocol review. In expert markets, the team is the agency.

Your buyers detect borrowed expertise in one meeting. Assume they will.

The same logic governs your conference and publication presence. Sponsors scan who from your firm is actually invited to speak on operations panels, whose methods papers get cited, and which of your leaders journal editors quote when a trial story breaks. An agency that builds that bench methodically, placing your operators where peers judge operators, creates an asset competitors cannot copy with budget. One that buys you lifestyle coverage in general business titles creates a clipping file your buyers will never open. Ask every candidate which three conferences matter most in your lead therapeutic area and who won the argument at each last year. Silence is an answer.

IX. Consilium

Weight crisis steadiness and site empathy alongside sponsor polish

The wider healthcare collection is indexed in the resources library, and engagement structures are set out on the public relations services page. CRO leaders will find shared ground in the guide for digital health startups, where the same participants judge software by similar standards.

Frequently asked questions

Should our agency also run our patient recruitment campaigns?

It can, if recruitment is staffed as its own discipline with community knowledge and ethics review, not as a side offer from the corporate team. Ask how campaigns are consented, how community partners are compensated, and how results are reported back to participants. Vague answers are disqualifying.

How do we talk publicly about a trial that missed its timeline?

State the operational facts you are permitted to share, what changed, and what the change protects: data quality, participant safety, endpoint integrity. Sponsors respect firms that explain delays in the language of rigour. They blacklist firms whose statements read like weather reports from another planet.

Can PR help us win sites, not just sponsors?

Yes, and this is undervalued. Sites choose between competing studies from the same sponsors. A CRO known for honest feasibility, sane visit schedules and respectful site communications fills its studies faster. Your agency should be producing site facing material with the same care as sponsor decks.

What belongs in our thought leadership if we cannot discuss client studies?

Methods, benchmarks and ethics: feasibility science, decentralised operations, participant burden research, therapeutic area recruitment patterns. The Tufts and CISCRP data ecosystem gives you plenty to analyse without touching a client's compound. Agencies that say there is nothing to write about have not read the field.

How should we handle diversity claims in our marketing?

Only with documentation: actual enrollment demographics where you may publish them, named community partnerships, operational specifics like translated consent and transport support. The FDA participation agenda makes this a scrutinised claim category. Your agency should audit every diversity sentence annually.

What metrics should a CRO expect from its agency?

Movement in the rooms where studies are awarded: sponsor meeting quality, shortlist invitations, site acceptance rates for your studies, participant inquiry quality, and accurate trade coverage of your methods. Impressions on social platforms are the weakest currency in this industry.

Do we need different agencies for different therapeutic areas?

Rarely. You need one agency with genuine clinical literacy and the humility to build area specific advisory input. Splitting agencies by therapy fragments your factual spine and doubles your review burden.

How this guide was built

The enrollment and retention figures here come from Tufts Center for the Study of Drug Development benchmarking as reported by trade and specialist sources, and the decentralization material from FDA guidance summaries by regulatory publishers. The limitation is vintage: the most detailed site performance dataset widely cited is the Tufts work reported in 2013, with a later benchmarking update reported in 2020, and the field has moved since both. Treat the percentages as the documented shape of a persistent problem rather than this quarter's scoreboard, and ask any agency you hire which current benchmarks they track in place of inherited numbers.

X. Incipe

Where Frontier Industries fits in this decision

Frontier Industries serves healthcare companies that sell to expert buyers, and CROs are the purest case: your customers audit claims for a living. The practice works the three registers this guide separates, sponsor credibility, site respect and participant clarity, from one factual spine. Meet the people on the about page, and read the sibling guide for medical device manufacturers if your trials involve device endpoints.

Bring your hardest study story, the one your team tells internally, to the first conversation. Reach the team through the industry campaign page or by phone at 401-219-4207.

Sources

1. Imperial CRS, The Facts on Patient Enrollment Delays, summarising Tufts CSDD research. https://www.imperialcrs.com/blog/patient-recruitment-and-retention/the-facts-on-patient-enrollment-delays/?hilite=workstream 2. Regulatory Affairs Professionals Society, Study: Clinical Trial Site Activation, Enrollment Difficulties Slow Product Approvals. https://www.raps.org/resource/study-clinical-trial-site-activation-enrollment.html 3. Applied Clinical Trials, Drug Developers Are Making Strides in Streamlining Patient Recruitment & Retention for Clinical Trials. https://www.appliedclinicaltrialsonline.com/view/drug-developers-making-strides-streamlining-patient-recruitment-and-retention 4. Drug Development News, Drug Developers Are Making Strides in Streamlining Patient Recruitment & Retention. https://drug-dev.com/drug-developers-are-making-strides-in-streamlining-patient-recruitment-retention-for-clinical-trials/ 5. NSF, FDA Guidance on Implementing Decentralized Elements in Clinical Trials, 2024. https://www.nsf.org/th/en/life-science-news/fda-guidance-implementing-decentralized-elements-clinical-trials 6. Freyr Solutions, FDA issues final guidance on conducting clinical trials with decentralized elements, 2024. https://www.freyrsolutions.com/mandate/fda-issues-final-guidance-on-conducting-clinical-trials-with-decentralized-elements 7. Crucial Data Solutions, Decentralized Clinical Trials: Costs, Regulations & Platforms. https://www.crucialdatasolutions.com/decentralized-clinical-trials/ 8. IntuitionLabs, Decentralized Clinical Trials (DCTs): How They Work & Benefits. https://intuitionlabs.ai/articles/decentralized-clinical-trials-guide 9. Mondaq, FDA Issues Guidance On Remote Clinical Trial Activities, Duane Morris, 2024. https://www.Mondaq.com/unitedstates/healthcare/1534202/fda-issues-guidance-on-remote-clinical-trial-activities 10. Clinical Trial Vanguard, How FDA's Guidance on Decentralized Trials Applies to Community-based Research Execution and Compliance, 2025. https://www.clinicaltrialvanguard.com/opinion/how-fdas-guidance-on-decentralized-trials-applies-to-community-based-research-execution-and-compliance/